When was Neion Bio founded?

Neion Bio was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Neion Bio located?

Neion Bio is headquartered in New York City, United States.

Is Neion Bio a funded company?

Neion Bio is a funded company, having raised a total of $23M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 27, 2026.

When was the latest funding round of Neion Bio?

Neion Bio's latest funding was a $***** Series A round on Jun 11, 2026, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.59B in funding in 2026 to date.

Where does Neion Bio rank among its competitors?

Neion Bio ranks 17th amongst 69 active competitors, of which 20 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was WhiteLab Genomics, which secured $26M in Oct, 2026.

Who are the top competitors of Neion Bio?

Neion Bio's top competitors include Senti Bio, ADARx Pharmaceuticals and Geninus. Among them, WhiteLab Genomics secured the most recent funding round in October, 2026.

Neion Bio - 2026 Company Profile, Funding & Competitors

Neion Bio is a series A company based in New York City (United States), founded in 2024. It operates as a Developer of life-saving products derived from nature's molecular factories. Neion Bio has raised $23M in funding from Caffeinated. The company has 69 active competitors, including 20 funded and 14 that have exited. Its top competitors include companies like Senti Bio, ADARx Pharmaceuticals and Geninus.

Company Details

Developer of life-saving products derived from nature's molecular factories. The company utilizes advanced genetic engineering that harness the power of biology to develop innovative solutions. Its technology leverages the principles of evolutionary biology to create transformative products.

Key Metrics

Founded Year

2024

Location

New York City, United States

Stage

Series A

Total Funding

$23M in 2 rounds

Latest Funding Round

Series A, Jun 11, 2026, $*****

Investors

Caffeinated & 5 more

Ranked

17^th among 69 active competitors

Similar Companies

Senti Bio & 84 more

View Neion Bio's full profile

Neion Bio has raised a total funding of $23M over 2 rounds. Its first funding round was on Mar 27, 2026. Its latest funding round was a Series A round on Jun 11, 2026 for $*****. 6 investors participated in its latest round. Neion Bio has 6 institutional investors.

Here is the list of recent funding rounds of Neion Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 11, 2026	9221519	Series A	9342578	9110919	3189452	2849564
Mar 27, 2026	7051685	Seed	5586625	3949733	Caffeinated	Basis Set Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Neion Bio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neion Bio include Senti Bio, ADARx Pharmaceuticals and Geninus. Here is the list of Top 10 competitors of Neion Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 31 others	68/100
2nd	ADARx Pharmaceuticals 2019, San Diego (United States), Public	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Bain Capital Life Sciences, T. Rowe Price ... & 17 others	64/100
3rd	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	62/100
4th	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	60/100
5th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	57/100
6th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	57/100
7th	WhiteLab Genomics 2019, Paris (France), Series B	Provider of drug discovery and development platform	$36.6M	AVP, Y Combinator & 5 others	57/100
8th	Modular Genetics 2000, Woburn (United States), Series B	Developer of a proprietary, automated system for gene engineering and molecular biology	$8.9M	MassVentures, America’s Seed Fund & 2 others	53/100
9th	Avectas 2011, Dublin (Ireland), Series C	Provider of non-viral cell engineering technology platform for drug discovery	$33.5M	EIC Fund, Europa & 1 others	50/100
10th	GeneScience Pharmaceuticals 1996, Changchun (China), Series B	Provides genetically engineered pharmaceuticals products	-	Haitong Bank, China Huarong Asset Management ... & 3 others	50/100
17th	Neion Bio 2024, New York City (United States), Series A	Developer of life-saving products derived from nature's molecular factories	$23M	Digitalis Ventures, Ensemble & 4 others	44/100